Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome

Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer

(2010) E. A. Reijm et al.   BREAST CANCER RESEARCH AND TREATMENT

MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β

(2010) Paul Cao et al.   Molecular Cancer

Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model

(2009) Janaiah Kota et al.   CELL

Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells

(2009) F. Sun et al.   MOLECULAR CANCER THERAPEUTICS

Maintenance of Undifferentiated State and Self-Renewal of Embryonic Neural Stem Cells by Polycomb Protein Ring1B

(2009) Mónica Román-Trufero et al.   STEM CELLS

Stem cell regulation by polycomb repressors: postponing commitment

(2008) Alexandra M Pietersen et al.   CURRENT OPINION IN CELL BIOLOGY

MicroRNA-26a Targets the Histone MethyltransferaseEnhancer of Zeste homolog 2during Myogenesis

(2008) Chung Fai Wong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1

(2008) M E Gonzalez et al.   ONCOGENE

Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer

(2008) S. Varambally et al.   SCIENCE

Polycomb Group Genes: Keeping Stem Cell Activity in Balance

(2008) Martin Sauvageau et al.   PLOS BIOLOGY